About us
Founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix) and Pr Olivier Tillement (Professor of Chemistry at University of Lyon), NH TherAguix is a French biotechnology company based in Grenoble. NH TherAguix has developed an innovative theranostic nanodrug called AGuIX® that allows to fight more efficiently against all forms of cancer.
Thanks to a €13M fund raising in 2019 (BPI, Innobio, Omnes, Arbevel, Supernova), NH THerAguix was able to launch a promising portfolio of clinical trials.
Partners






